Day One |
|
7:30 a.m. |
Registration |
8:00 a.m. |
Opening Remarks |
8:05 a.m. |
Keynote Address:
New Era in Cell Therapy: From CAR-T to Solid Tumor |
|
Renier Brentjens, M.D., Ph.D.
Director-Cellular Therapies
Memorial Sloan Kettering |
session i |
Adoptive Cell Therapies |
8:45 a.m. |
Q&A |
8:55 a.m. |
Novel CARs and TCRs |
|
Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc
Poseida Therapeutics, Inc.
Speaker to be announced
Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited |
9:40 a.m. |
Q&A |
9:45 a.m. |
Allogenic Platforms |
|
Andre Koulika, Ph.D.
Chief Executive Officer
Cellectis SA
CRISPR Therapeutics AG
Speaker to be announced
Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc. |
10:20 a.m. |
Q&A |
10:25 a.m. |
Coffee Break |
10:40 a.m. |
Other Cell Types (NK and TILs) |
|
Bob Valamehr, Ph.D.
Vice President-Immunotherapy
Fate Therapeutics, Inc.
Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc. |
11:10 a.m. |
Q&A |
11:15 a.m. |
Safety Issues of Cell Therapies |
|
David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc. |
11:35 a.m. |
Q&A |
11:40 a.m. |
Cytokines |
|
Deborah Charych, Ph.D.
Executive Director - Research and Development
Nektar Therapeutics
Martin Oft, M.D.
Founder and Vice President, Pre-Clinical and Clinical Development
ARMO Biosciences, Inc. |
12:10 p.m. |
Break |
12:25 p.m. |
Lunch Panel: Setting Up Commercial Cell Therapy Products
in Academic Center / Q&A |
|
Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service
Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center |
session ii |
Jump Starting the Immune System |
1:00 p.m. |
Break |
1:15 p.m. |
Cancer Therapeutic Vaccines Overview |
|
Col. (ret.) George E. Peoples, M.D., F.A.C.S., MC, USA
Founder and CEO, Cancer Insight, LLC;
Director-Cancer Vaccine Development Program, Metis Foundation;
Professor of Surgery, Uniformed Services University;
Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center |
1:35 a.m. |
Q&A |
1:40 p.m. |
Oncolytic Viruses |
|
Oncolytic Viruses Making Tumors Hot
Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery
University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute |
2:05 a.m. |
Q&A |
2:10 p.m. |
Keynote II:
Building a Leader in Cell Therapy-Challenges Facing
Clinical and Commercial Strategies |
|
Pascal Touchon, D.V.M.
Senior Vice President, Global Head-Cell and Gene
Novartis Oncology |
2:55 a.m. |
Q&A |
3:00 p.m. |
Coffee Break |
3:10 p.m. |
In Situ Vaccination |
|
Joshua Brody, M.D.
Director-Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science
and Medicine |
3:30 a.m. |
Q&A |
3:35 p.m. |
Toll Like Receptor Agonists |
|
Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax Technologies Corporation
Joanna Horobin, M.D.
Chief Medical Officer
Idera Pharmaceuticals, Inc. |
4:05 a.m. |
Q&A |
4:10 p.m. |
STING Agonists |
|
Natalie Sacks, M.D.
Chief Medical Officer
Aduro Biotech, Inc
R.P. "Kris" Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals |
4:45 p.m. |
Q&A |
4:50 p.m. |
Reception |
Day Two |
|
7:30 a.m. |
Registration |
8:00 a.m. |
Opening Remarks |
8:05 a.m. |
Keynote III:
Personalized Cancer Immunotherapies |
|
Ira Mellman, Ph.D.
Vice President-Cancer Immunology
Genentech, Inc. |
8:50 a.m. |
Q&A |
Session III |
Next generation approaches |
8:55 a.m. |
Neoantigens |
|
John Castle, Ph.D.
Head-Translational Medicine and Bioinformatics
Agenus Inc.
Gritstone Oncology
Speaker to be announced
Genocea Biosciences, Inc.
Speaker to be announced |
9:40 a.m. |
Q&A |
9:45 a.m. |
Keynote IV:
Optimizing the Immune Microenvironment in Prostate Cancer |
|
Ravi Madan, M.D.
Clinical Director-Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute |
10:25 a.m. |
Q&A |
10:30 a.m. |
Coffee Break |
10:40 a.m. |
Tumor Microenvironment: MDSCs and Tregs |
|
The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on
Suppressive Myeloid Cells |
|
Catherine Sabatos-Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research |
|
Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc. |
11:15 a.m. |
Q&A |
11:20 a.m. |
Tumor Microenvironment: Metabolites/Enzymes |
|
Charles Link Jr. M.D.
Chief Executive Officer
NewLink Genetics Corporation
Keith Orford, M.D., Ph.D.
Senior Vice President of Clinical Development
Calithera Biosciences, Inc. |
11:50 a.m. |
Q&A |
11:55 a.m. |
Break |
12:05 p.m. |
Lunch Panel: Economics of Immunotherapies and
Immunotherapy Combinations |
| |
Bryon Wornson, moderator
Vice President-Global Health and Value
Pfizer Inc. |
| |
Ed Schoonveld
Managing Principal, Value
& Access ZS Associates
|
|
Ed Pezalla, M.D.,
Former National Medical Director for Pharmaceutical Policy and Strategy
Aetna
|
|
Sophie Opdyke
VP & Immuno-Oncology Lead - Global Marketing and Commercial
Development
Pfizer
|
Session IV |
Immunotherapy Combinations |
1:00 p.m. |
Keynote V:
Clinical Combination Strategies in Immunotherapy |
|
Roger Dansey, M.D.
Senior Vice President-Global Clinical Development Oncology
Merck Research Laboratories, Merck & Co. |
1:40 p.m. |
Q&A |
1:45 p.m. |
Developing Rational Combinations in Immuno-Oncology |
|
Ruslan Novosiadly, M.D., Ph.D.
Senior Research Advisor
Experimental & Translational Immunooncology
Department of Cancer Immunobiology
Eli Lilly & Company
|
2:05 p.m. |
Q&A |
2:10 p.m. |
Targeted Therapy Combinations With Immunotherapy |
|
Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early Development and
Translational Oncology
Pfizer Inc. |
2:30 p.m. |
Q&A |
2:35 p.m. |
Coffee Break |
2:50 p.m. |
Personalized Immunotherapy for NSCLC |
|
Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief-Medical Oncology,
Associate Director-Translational Research, Director-Thoracic
Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine |
3:20 p.m. |
Q&A |
3:25 p.m. |
Immunotherapy Combinations for Renal Cell or Urothelial Carcinoma |
|
Andrea Apolo, M.D.
Investigator-Genitourinary Malignancies Branch, Head-Bladder
Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH |
3:50 p.m. |
Q&A |
3:55 p.m. |
Microbiome in IO |
|
Bruce Roberts, Ph.D.
Chief Scientific Officer
Vedanta Biosciences
J.C. Gutierrez Ramos, Ph.D.
Chief Executive Officer
Synlogic |
4:25 p.m. |
Q&A |
4:30 p.m. |
Bispecifics |
|
Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V.
Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc. |
5:00 p.m. |
Q&A |
5:05p.m. |
Reception |
Speakers |
|
| |
Andrew Allen, M.D., Ph.D.
President and Chief Executive Officer
Gritstone Oncology |
| |
Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery
University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute |
| |
Andrea Apolo, M.D.
Investigator-Genitourinary Malignancies Branch, Head-Bladder
Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH |
| |
Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early
Development and Translational Oncology
Pfizer Inc. |
| |
Renier Brentjens, M.D., Ph.D.
Director-Cellular Therapies
Memorial Sloan Kettering |
| |
Joshua Brody, M.D.
Director-Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science
and Medicine |
| |
John Castle, Ph.D.
Head-Translational Medicine and Bioinformatics
Agenus Inc. |
| |
Deborah Charych, Ph.D.
Executive Director - Research and Development
Nektar Therapeutics |
| |
Andre Choulika, Ph.D.
Chief Executive Officer
Cellectis SA |
| |
Chip Clark
President and Chief Executive Officer
Genocea Biosciences, Inc.
|
| |
Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer
Dynavax Technologies Corporation |
| |
Roger Dansey, M.D.
Senior Vice President-Global Clinical Development Oncology
Merck Research Laboratories, Merck & Co. |
| |
Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc. |
| |
Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service, Melvin Berlin
Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center |
| |
J.C. Gutierrez Ramos, Ph.D.
Chief Executive Officer
Synlogic |
| |
Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc. |
| |
Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief-Medical Oncology,
Associate Director-Translational Research, Director-Thoracic
Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine |
| |
Joanna Horobin, M.D.
Chief Medical Officer
Idera Pharmaceuticals, Inc. |
| |
Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited |
| |
R.P. "Kris" Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals |
| |
Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc. |
| |
Charles Link Jr., M.D.
Chief Executive Officer
NewLink Genetics Corporation |
| |
Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V. |
| |
Ravi Madan, M.D.
Clinical Director-Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute |
| |
Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc. |
| |
Ira Mellman, Ph.D.
Vice President-Cancer Immunology
Genentech, Inc. |
| |
Ruslan Novosiadly, M.D., Ph.D.,
Senior Research Advisor
Experimental & Translational Immunooncology
Department of Cancer Immunobiology
Eli Lilly & Company
|
| |
Martin Oft, M.D.
Founder and Vice President, Pre-Clinical and Clinical
Development
ARMO Biosciences, Inc. |
| |
Sophie Opdyke
VP & Immuno-Oncology Lead - Global Marketing and Commercial
Development
Pfizer
|
| |
Keith Orford, M.D., Ph.D.,
Senior Vice President of Clinical Development
Calithera Biosciences, Inc. |
| |
Col. (ret.) George E. Peoples, M.D., FACS, MC, USA, Col. (ret.)
George E. Peoples, M.D., FACS, MC, USA
Founder and CEO, Cancer Insight, LLC; Director-Cancer Vaccine
Development Program, Metis Foundation; Professor of Surgery,
Uniformed Services University; Professor (adjunct) of Surgical
Oncology, MD Anderson Cancer Center |
| |
Ed Pezalla, M.D.,
Former National Medical Director for Pharmaceutical Policy and
Strategy, Aetna
|
| |
Thomas Potts Director
Global Pricing
Bristol-Myers Squibb
Interim CODE Lead |
| |
Bruce Roberts, Ph.D.
Chief Scientific Officer
Vedanta Biosciences |
| |
Catherine Sabatos-Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research |
| |
Natalie Sacks, M.D.
Chief Medical Officer
Aduro Biotech, Inc |
| |
Ed Schoonveld
Managing Principal, Value & Access
ZS Associates
|
| |
Devon Shedlock, Ph.D.
Vice President, Preclinical Development
Poseida Therapeutics, Inc.
|
| |
David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc. |
| |
Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc |
| |
Pascal Touchon, D.V.M.
Senior Vice President, Global Head-Cell and Gene
Novartis Oncology |
| |
Bob Valamehr, Ph.D.
Vice President-Immunotherapy
Fate Therapeutics, Inc. |
| |
Bryon Wornson
Vice President-Global Health and Value
Pfizer Inc. |